232 related articles for article (PubMed ID: 12736162)
1. Pancreatic vasopressin V1b receptors: characterization in In-R1-G9 cells and localization in human pancreas.
Folny V; Raufaste D; Lukovic L; Pouzet B; Rochard P; Pascal M; Serradeil-Le Gal C
Am J Physiol Endocrinol Metab; 2003 Sep; 285(3):E566-76. PubMed ID: 12736162
[TBL] [Abstract][Full Text] [Related]
2. Vasopressin stimulates insulin release from islet cells through V1b receptors: a combined pharmacological/knockout approach.
Oshikawa S; Tanoue A; Koshimizu TA; Kitagawa Y; Tsujimoto G
Mol Pharmacol; 2004 Mar; 65(3):623-9. PubMed ID: 14978240
[TBL] [Abstract][Full Text] [Related]
3. Effects of arginine vasopressin and oxytocin on glucagon release from clonal alpha-cell line In-R1-G9: involvement of V1b receptors.
Yibchok-anun S; Hsu WH
Life Sci; 1998; 63(21):1871-8. PubMed ID: 9825765
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells.
Tahara A; Saito M; Sugimoto T; Tomura Y; Wada K; Kusayama T; Tsukada J; Ishii N; Yatsu T; Uchida W; Tanaka A
Br J Pharmacol; 1998 Dec; 125(7):1463-70. PubMed ID: 9884074
[TBL] [Abstract][Full Text] [Related]
5. Mutual regulation of vasopressin- and oxytocin-induced glucagon secretion in V1b vasopressin receptor knockout mice.
Fujiwara Y; Hiroyama M; Sanbe A; Yamauchi J; Tsujimoto G; Tanoue A
J Endocrinol; 2007 Feb; 192(2):361-9. PubMed ID: 17283236
[TBL] [Abstract][Full Text] [Related]
6. Biological characterization of rodent and human vasopressin V1b receptors using SSR-149415, a nonpeptide V1b receptor ligand.
Serradeil-Le Gal C; Raufaste D; Derick S; Blankenstein J; Allen J; Pouzet B; Pascal M; Wagnon J; Ventura MA
Am J Physiol Regul Integr Comp Physiol; 2007 Aug; 293(2):R938-49. PubMed ID: 17522130
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
Pena A; Murat B; Trueba M; Ventura MA; Wo NC; Szeto HH; Cheng LL; Stoev S; Guillon G; Manning M
J Med Chem; 2007 Feb; 50(4):835-47. PubMed ID: 17300166
[TBL] [Abstract][Full Text] [Related]
8. Vasopressin promotes cardiomyocyte hypertrophy via the vasopressin V1A receptor in neonatal mice.
Hiroyama M; Wang S; Aoyagi T; Oikawa R; Sanbe A; Takeo S; Tanoue A
Eur J Pharmacol; 2007 Mar; 559(2-3):89-97. PubMed ID: 17275806
[TBL] [Abstract][Full Text] [Related]
9. Effects of YM471, a nonpeptide AVP V(1A) and V(2) receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells.
Tsukada J; Tahara A; Tomura Y; Wada Ki ; Kusayama T; Ishii N; Yatsu T; Uchida W; Taniguchi N; Tanaka A
Br J Pharmacol; 2001 Jul; 133(5):746-54. PubMed ID: 11429400
[TBL] [Abstract][Full Text] [Related]
10. Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors.
Serradeil-Le Gal C; Wagnon J; Garcia C; Lacour C; Guiraudou P; Christophe B; Villanova G; Nisato D; Maffrand JP; Le Fur G
J Clin Invest; 1993 Jul; 92(1):224-31. PubMed ID: 8392086
[TBL] [Abstract][Full Text] [Related]
11. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.
Yamamura Y; Nakamura S; Itoh S; Hirano T; Onogawa T; Yamashita T; Yamada Y; Tsujimae K; Aoyama M; Kotosai K; Ogawa H; Yamashita H; Kondo K; Tominaga M; Tsujimoto G; Mori T
J Pharmacol Exp Ther; 1998 Dec; 287(3):860-7. PubMed ID: 9864265
[TBL] [Abstract][Full Text] [Related]
12. Lack of effect of a selective vasopressin V1A receptor antagonist SR 49,059, on potentiation by vasopressin of adrenoceptor-mediated pressor responses in the rat mesenteric arterial bed.
Heinemann A; Horina G; Stauber RE; Pertl C; Holzer P; Peskar BA
Br J Pharmacol; 1998 Nov; 125(6):1120-7. PubMed ID: 9863637
[TBL] [Abstract][Full Text] [Related]
13. Functional and pharmacological characterization of the first specific agonist and antagonist for the V1b receptor in mammals.
Serradeil-Le Gal C; Derick S; Brossard G; Manning M; Simiand J; Gaillard R; Griebel G; Guillon G
Stress; 2003 Sep; 6(3):199-206. PubMed ID: 13129813
[TBL] [Abstract][Full Text] [Related]
14. The vasopressin-induced excitation of hypoglossal and facial motoneurons in young rats is mediated by V1a but not V1b receptors, and is independent of intracellular calcium signalling.
Reymond-Marron I; Tribollet E; Raggenbass M
Eur J Neurosci; 2006 Sep; 24(6):1565-74. PubMed ID: 17004920
[TBL] [Abstract][Full Text] [Related]
15. Analysis of interactions responsible for vasopressin binding to human neurohypophyseal hormone receptors-molecular dynamics study of the activated receptor-vasopressin-G(alpha) systems.
Slusarz MJ; Giełdoń A; Slusarz R; Ciarkowski J
J Pept Sci; 2006 Mar; 12(3):180-9. PubMed ID: 16114100
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a novel nonpeptide vasopressin V(2)-agonist, OPC-51803, in cells transfected human vasopressin receptor subtypes.
Nakamura S; Yamamura Y; Itoh S; Hirano T; Tsujimae K; Aoyama M; Kondo K; Ogawa H; Shinohara T; Kan K; Tanada Y; Teramoto S; Sumida T; Nakayama S; Sekiguchi K; Kambe T; Tsujimoto G; Mori T; Tominaga M
Br J Pharmacol; 2000 Apr; 129(8):1700-6. PubMed ID: 10780976
[TBL] [Abstract][Full Text] [Related]
17. Similarities between hamster pancreatic islet beta (HIT) cell vasopressin receptors and V1b receptors.
Richardson SB; Laya T; VanOoy M
J Endocrinol; 1995 Oct; 147(1):59-65. PubMed ID: 7490538
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological characterization of YM087, a potent, nonpeptide human vasopressin V1A and V2 receptor antagonist.
Tahara A; Saito M; Sugimoto T; Tomura Y; Wada K; Kusayama T; Tsukada J; Ishii N; Yatsu T; Uchida W; Tanaka A
Naunyn Schmiedebergs Arch Pharmacol; 1998 Jan; 357(1):63-9. PubMed ID: 9459574
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivo.
Tahara A; Tomura Y; Wada KI; Kusayama T; Tsukada J; Takanashi M; Yatsu T; Uchida W; Tanaka A
J Pharmacol Exp Ther; 1997 Jul; 282(1):301-8. PubMed ID: 9223568
[TBL] [Abstract][Full Text] [Related]
20. V1a- and V2-type vasopressin receptors mediate vasopressin-induced Ca2+ responses in isolated rat supraoptic neurones.
Gouzénes L; Sabatier N; Richard P; Moos FC; Dayanithi G
J Physiol; 1999 Jun; 517 ( Pt 3)(Pt 3):771-9. PubMed ID: 10358117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
